Buprenorphine was developed as an opioid agonist, which is a type of partial agonist. It has been shown to effectively relieve pain and the discomfort caused by various kinds of withdrawal, such as that caused by drug addiction. Buprenorphine can be used as an extended-release (ER) drug. This type of drug allows the patient to have more control over their dosage and therefore to be able to continue with the program longer than would be possible with a shorter term (conventional) heroin or morphine analog. It is also believed to reduce dependence on the drug, as compared to other opioids such as oxycodone and hydrocodone. Buprenorphine belongs to the family of narcotics, along with codeine and hydrocodone, and is a derivative of codeine. It is available in different formulations such as tablets, liquids, powders, and injection devices.
Increase in opioid epidemic in the U.S. is expected to drive growth of the global buprenorphine market during the forecast period. The opioid epidemic refers to the misuse or overuse of addictive opioid drugs with significant social, medical, and economic consequences such as death due to overdose. According to the U.S. Department of Health and Human Services, in 2018, around 10.3 million people aged 12 years and above misused opioids. According to the same source, around 9.9 million people misused prescription pain relievers, while 808,000 people used heroin. Moreover, in 2016, the national rate of opioid-associated hospitalization was 297 per 100,000 population. Buprenorphine is mainly used in the treatment of an opioid-related disorder. It can be administered intravenously, as a skin patch, or keeping it under the tongue. Thus, these factors are expected to drive growth of the global buprenorphine market during the forecast period. Moreover, the presence of a large number of buprenorphine manufacturers is expected to propel the global buprenorphine market growth over the forecast period.
However, side-effects related to buprenorphine such as dizziness, fever, tremors, sweating, diarrhea, and nausea are expected to hinder the global buprenorphine market growth over the forecast period. Among regions, North America is expected to witness significant growth in the global buprenorphine market during the forecast period. This is owing to stringent policies by government authorities to control the crisis of the opioid epidemic. Furthermore, an awareness campaign by the government is expected to boost the regional market growth in the near future.
Key companies involved in the global buprenorphine market are Faran Shimi Pharmaceutical Co., Siegfried, Micro Orgo Chem, Sanofi, Rusan Pharma, Johnson Matthey, Sun Pharmaceutical Industries Ltd., Johnson Matthey, Noramco, Resonance-labs, Mallinckrodt, Teva Pharmaceutical Industries Ltd., Arevipharma GmbH, and Unichem Laboratories.
For instance, in June 2019, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for the first generic version of Narcan, naloxone hydrochloride nasal spray indicated for opioid overdose.
No comments:
Post a Comment